[Iron-chelating treatment].
Vullo
C
C
Di Palma
A
A
De Sanctis
V
V
Borgatti
L
L
Atti
G
G
D015913:Chelation Therapy; D000077543:Deferiprone; D003676:Deferoxamine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004920:Erythropoiesis; D006486:Hemosiderosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007501:Iron; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D004369:Pentetic Acid / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D013789:Thalassemia / Q000150:complications* / Q000378:metabolism
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D004369:Pentetic Acid; D007501:Iron; D003676:Deferoxamine
Trattamento ferrochelante.